ORCHARD THERAPEUTICS PLC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About ORTX
Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Find out what a historical investment in ORCHARD THERAPEUTICS PLC would be worth today using our ORTX stock calculator.
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountORTX FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ORTX
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in ORTX
on Stake
Buy ORTX from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of ORTX from only US$10 with fractional shares
